MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1245/s10434-025-18311-8

Медицинская библиотека · Annals of surgical oncology · 2025

Comparison of Pretreatment Strategies for cT2cN0 Staged Adenocarcinoma of the Esophagus and the Gastroesophageal Junction: A European High-Volume Center Cohort Analysis.

Wirsik Naita M, Schmidt Thomas, Kooij Cezanne D, Dempster Niall, Crnovrsanin Nerma, Donlon Noel E, Uzun Eren, Bhanot Kunal, Nienhüser Henrik, Polette Daniela, Kewani Kammy, Grimminger Peter, Reim Daniel, Seyfried Florian, Fuchs Hans F, Gisbertz Suzanne S, Germer Christoph-Thomas, Ruurda Jelle P, Klevebro Fredrik, Schröder Wolfgang, Nilsson Magnus, Reynolds John V, Van Berge Henegouwen Mark I, Markar Sheraz, Van Hillegersberg Richard, Bruns Christiane J

СтатьяСравнительное исследованиеМногоцентровое исследованиеПеревод пока не подготовлен

Аннотация

After the ESOPEC trial showed a survival benefit for fluorouracil, leucovorin, oxaliplatin, and docetaxel (FLOT)-treated adenocarcinomas of the esophagus (EAC) and the gastroesophageal junction (GEJ) compared with Chemoradiotherapy for Oesophageal Cancer Followed by Surgery Study (CROSS), a European, high-volume center study for stage cT2cN0 EAC and GEJ was undertaken, as it has been published that a third of these patients are understaged and could benefit from a multimodal approach PATIENTS AND

METHODS

Retrospective analysis of prospective databases from ten high-volume European centers was performed. Inclusion criteria were GEJ Siewert type I/II or EAC with cT2cN0 status at diagnosis undergoing multimodal treatment with FLOT or CROSS. Primary endpoint was overall survival (OS)

RESULTS

Between 2012 and 2023, 133 patients met the inclusion criteria, of whom 73 (54.9%) received CROSS and 60 (45.1%) underwent treatment with FLOT. In both groups, patients were mainly male (p = 0.08), older than 70 years (p = 0.24), and had American Society of Anesthesiologists (ASA) II classification (p = 0.45). Regarding surgical treatment, more patients underwent gastrectomy in the FLOT than in the CROSS cohort (23.3% versus 6.8%, p = 0.007). There were no differences regarding pT, pN, and pM category (p > 0.05). Median survival was not reached, while mean survival was 74.6 months (95% CI 60.5-88.7 months) for CROSS versus 100.8 months (95% CI 72.5-94.5 months, p = 0.028) for FLOT. The 3-year survival was 87% in the FLOT group versus 59% in the CROSS group. In multivariable analyses, FLOT was independent factor for survival (p < 0.001)

CONCLUSIONS

For cT2cN0 staged EAC and GEJ type I /II patients FLOT chemotherapy showed a survival benefit and should be the preferred treatment in a multimodal approach.

Для цитирования: Wirsik Naita M, Schmidt Thomas, Kooij Cezanne D, Dempster Niall, Crnovrsanin Nerma, Donlon Noel E, Uzun Eren, Bhanot Kunal, Nienhüser Henrik, Polette Daniela, Kewani Kammy, Grimminger Peter, Reim Daniel, Seyfried Florian, Fuchs Hans F, Gisbertz Suzanne S, Germer Christoph-Thomas, Ruurda Jelle P, Klevebro Fredrik, Schröder Wolfgang, Nilsson Magnus, Reynolds John V, Van Berge Henegouwen Mark I, Markar Sheraz, Van Hillegersberg Richard, Bruns Christiane J. Comparison of Pretreatment Strategies for cT2cN0 Staged Adenocarcinoma of the Esophagus and the Gastroesophageal Junction: A European High-Volume Center Cohort Analysis.. Annals of surgical oncology. 2025. DOI: 10.1245/s10434-025-18311-8.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.